Zacks: Analysts Anticipate Agile Therapeutics Inc (NASDAQ:AGRX) to Post -$0.11 EPS

Equities research analysts forecast that Agile Therapeutics Inc (NASDAQ:AGRX) will post ($0.11) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Agile Therapeutics’ earnings. The lowest EPS estimate is ($0.13) and the highest is ($0.09). Agile Therapeutics posted earnings per share of ($0.16) in the same quarter last year, which suggests a positive year over year growth rate of 31.3%. The company is expected to issue its next earnings results on Friday, August 2nd.

According to Zacks, analysts expect that Agile Therapeutics will report full-year earnings of ($0.44) per share for the current financial year, with EPS estimates ranging from ($0.52) to ($0.39). For the next year, analysts expect that the firm will report earnings of ($0.42) per share, with EPS estimates ranging from ($0.85) to $0.11. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Agile Therapeutics.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.02).

A number of equities analysts have commented on AGRX shares. Maxim Group restated a “buy” rating and issued a $3.00 price target on shares of Agile Therapeutics in a research report on Monday, February 11th. Janney Montgomery Scott started coverage on shares of Agile Therapeutics in a research report on Friday, April 12th. They issued a “buy” rating and a $4.00 price target on the stock. ValuEngine upgraded shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 11th. Finally, Oppenheimer initiated coverage on shares of Agile Therapeutics in a research report on Thursday, June 6th. They issued an “outperform” rating and a $5.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $4.00.

In related news, CEO Alfred Altomari bought 20,000 shares of Agile Therapeutics stock in a transaction dated Monday, June 10th. The shares were bought at an average cost of $1.27 per share, for a total transaction of $25,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have bought 65,000 shares of company stock worth $94,700 over the last quarter. 8.50% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. lifted its position in shares of Agile Therapeutics by 15.7% during the fourth quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock worth $77,000 after purchasing an additional 18,038 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Agile Therapeutics by 24.0% during the fourth quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 44,639 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Agile Therapeutics by 33.3% during the first quarter. Acadian Asset Management LLC now owns 417,269 shares of the specialty pharmaceutical company’s stock worth $630,000 after purchasing an additional 104,222 shares in the last quarter. Advisor Group Inc. lifted its position in shares of Agile Therapeutics by 716.7% during the first quarter. Advisor Group Inc. now owns 147,000 shares of the specialty pharmaceutical company’s stock worth $222,000 after purchasing an additional 129,000 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Agile Therapeutics by 10.0% during the first quarter. Renaissance Technologies LLC now owns 2,133,777 shares of the specialty pharmaceutical company’s stock worth $3,222,000 after purchasing an additional 193,100 shares in the last quarter. Institutional investors own 42.38% of the company’s stock.

NASDAQ:AGRX traded up $0.06 on Tuesday, reaching $1.33. The stock had a trading volume of 181,562 shares, compared to its average volume of 404,681. The firm has a market cap of $56.86 million, a PE ratio of -2.29 and a beta of 0.64. Agile Therapeutics has a 1-year low of $0.23 and a 1-year high of $1.70. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.01.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Further Reading: Momentum Indicators

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.